Clinical trial

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

NCT00831233

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2009-04-01

PhasePHASE3

Study timeline

Study start (unknown)2009-04-01Date precision: month

Registry last updated2013-11-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

DegarelixDRUG · verified · RxNorm: degarelix

GoserelinDRUG · verified · RxNorm: goserelin

BicalutamideDRUG · verified · RxNorm: bicalutamide

Sponsors & collaborators

Ferring Pharmaceuticalslead sponsor

Mapped research locations

LondonUnited Kingdom3 MadridSpain2 BarcelonaSpain1 HamburgGermany1 SevilleSpain1 DresdenGermany1 LeipzigGermany1 GlasgowUnited Kingdom1 CologneGermany1 A CoruñaSpain1 SheffieldUnited Kingdom1 BristolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00831233 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.